The new app brings hope to 70,000 cancer patients seeking reliable information to navigate their treatment journey
Pune (Maharashtra) [India], June 15: Cancer patients in India now have access to CURIA, a first-of-its-kind app developed by Swiss company OncoCoin AG, the most decentralized and equitable ecosystem of cancer information. CURIA, with a global community of over 150,000, empowers patients with individualised information on treatments, clinical trials and experts. It provides them with the much-needed support to navigate the tough decisions throughout their treatment journey.
According to a report by WHO, 1 in every 10 Indians will develop cancer in their lifetime.There were as many as 1.16 million new cancer cases and 784,800 cancer deaths in 2018 alone. High mortality, combined with over 500 types of cancers, has generated a need for highly relevant information more than ever before.
CURIA empowers patients and their families with individualized information about approved therapies, clinical trials, and medical experts. Built over the OncoCoin platform, CURIA offers services such as tailored information, second opinion, and the opportunity to participate in research programmes. The timely availability of this information at patient’s fingertips helps them navigate through tough decisions throughout their treatment journey.
Speaking of this, Amit Ananpara, Innoplexus India Co-MD, said “Globally, 70% of cancer patients feel they do not get the information they need to make informed decisions. Specifically in India, limited knowledge of ongoing clinical trials leaves a gap in research involvement, stifling new insights. CURIA has successfully bridged such gaps in Europe. We look forward to helping cancer patients in India in their journey to cure.”
 World Health Organisation. (2020). World Cancer Report: Cancer Research for Cancer
Prevention. Available at: https://publications.iarc.fr/586
Mekuria AB, Erku DA, Belachew S. (2016). Preferred information sources and needs of cancer
patients on disease symptoms and management: a cross-sectional study. Patient Prefer
Adherence. 10:1991-1997. https://doi.org/10.2147/PPA.S116463